中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.034 seconds)

    UBE2T peptides and vaccines containing the same
    1.
    发明授权
    UBE2T peptides and vaccines containing the same 有权

    公开(公告)号：US11266729B2

    公开(公告)日：2022-03-08

    申请号：US16120102

    申请日：2018-08-31

    Applicant: OncoTherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: A61K39/00 ,  C12N5/0783 ,  C12N5/078 ,  C07K16/40 ,  A61K31/7088 ,  C12N9/00 ,  G01N33/574

    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

    UBE2T peptides and vaccines containing the same
    2.
    发明授权
    UBE2T peptides and vaccines containing the same 有权

    公开(公告)号：US10092634B2

    公开(公告)日：2018-10-09

    申请号：US14400169

    申请日：2013-09-09

    Applicant: OncoTherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: A61K39/00 ,  A61K31/7088 ,  C12N9/00 ,  C07K16/40 ,  G01N33/574

    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

    TOPK PEPTIDES AND VACCINES INCLUDING THE SAME
    4.
    发明申请
    TOPK PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    TOPK PEPTIDES和疫苗，包括它们

    公开(公告)号：US20140255437A1

    公开(公告)日：2014-09-11

    申请号：US14353261

    申请日：2012-10-25

    Applicant: c/o ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama

    IPC: A61K39/00 ,  C07K16/18 ,  C07K7/06

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/0005 ,  A61K2039/5154 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/4748 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/34 ,  C12N9/12 ,  C12N9/1205 ,  C12Y207/12002 ,  G01N33/505 ,  G01N33/574

    Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.

    Abstract translation: 本发明提供了源自TOPK的分离的表位肽，其免疫原性片段具有诱导细胞毒性T淋巴细胞（CTL）的能力，因此适用于癌症免疫治疗，更特别地，作为癌症疫苗。 本发明的肽包括包括TOPK衍生的氨基酸序列和其修饰形式的两种肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，只要这些修饰版本具有CTL 诱导性。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物组合物。 本发明的肽，多核苷酸和药物组合物在治疗和预防多种癌症中的任一者或两者中都具有特别的用途。

    METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES
    5.
    发明申请
    METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES 审中-公开
    通过管理WDRPUH EPITOPE肽诱导免疫应答的方法

    公开(公告)号：US20150315239A1

    公开(公告)日：2015-11-05

    申请号：US14805424

    申请日：2015-07-21

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: C07K7/06 ,  A61K39/00

    CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/1764 ,  A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C12N5/0638 ,  C12N5/0639

    Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

    Abstract translation: 本发明提供了含有SEQ ID NO：1,2,3,4，16，17，30，31，34，36，37，40，41，45，49，55，57和61的氨基酸序列的肽 ，以及含有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失，插入或添加，但仍具有细胞毒性T细胞诱导性。 本发明还提供了用于治疗或预防肿瘤的药物，其含有这些肽的药物。 本发明的肽也可以用作疫苗。

    CDCA1 epitope peptides and vaccines containing the same
    7.
    发明授权
    CDCA1 epitope peptides and vaccines containing the same 有权

    公开(公告)号：US10711047B2

    公开(公告)日：2020-07-14

    申请号：US15176444

    申请日：2016-06-08

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura

    IPC: A61K39/00 ,  C07K14/47 ,  C12N5/0783 ,  C07K7/06 ,  A61K38/00

    Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the CDCA1 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, breast cancer, bladder cancer, esophageal cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

    HJURP peptides and vaccines including the same
    10.
    发明授权
    HJURP peptides and vaccines including the same 有权
    HJURP肽和疫苗包括相同

    公开(公告)号：US09403890B2

    公开(公告)日：2016-08-02

    申请号：US14205163

    申请日：2014-03-11

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: C07K7/00 ,  A61K38/08 ,  C07K14/47 ,  C07K7/06 ,  C07K16/18 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00

    CPC classification number: C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

    Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find utility in the treatment of cancers, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

    Abstract translation: 本文描述了衍生自SEQ ID NO：50的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗。 本发明的肽包括上述氨基酸序列及其修饰形式，只要它们保留原始序列所需的细胞毒性T细胞诱导能力即可。 还提供了编码肽的核酸以及包括任何肽或核酸的药剂，物质和/或组合物。 本发明的肽，核酸，药物，物质和组合物可用于治疗癌症，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌，食道癌， 扩散型胃癌，肝癌，NSCLC，淋巴瘤，骨肉瘤，卵巢癌，胰腺癌，前列腺癌，肾癌，SCLC，软组织肿瘤和睾丸肿瘤。

Patent Agency Ranking